A-911
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Discovery of A-911, a potent, orally bioavailable 5-HT7 antagonist that promotes DC1-mediated T-cell cross-priming and anti-tumor immunity
(AACR 2026)
- "The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication."
Late-breaking abstract • Oncology • CD8 • IL12A
1 to 1
Of
1
Go to page
1